Literature DB >> 26240131

Breast Cancer Disparities: A Multicenter Comparison of Tumor Diagnosis, Characteristics, and Surgical Treatment in China and the U.S.

Priya G Sivasubramaniam1, Bai-Lin Zhang1, Qian Zhang1, Jennifer S Smith1, Bin Zhang1, Zhong-Hua Tang1, Guo-Ji Chen1, Xiao-Ming Xie1, Xiao-Zhou Xu1, Hong-Jian Yang1, Jian-Jun He1, Hui Li1, Jia-Yuan Li1, Jin-Hu Fan1, You-Lin Qiao2.   

Abstract

BACKGROUND AND
OBJECTIVE: Incidence of and mortality rates for breast cancer continue to rise in the People's Republic of China. The purpose of this study was to analyze differences in characteristics of breast malignancies between China and the U.S.
METHODS: Data from 384,262 breast cancer patients registered in the U.S. Surveillance, Epidemiology, and End Results (SEER) program from 2000 to 2010 were compared with 4,211 Chinese breast cancer patients registered in a Chinese database from 1999 to 2008. Outcomes included age, race, histology, tumor and node staging, laterality, surgical treatment method, and reconstruction. The Pearson chi-square and Fisher's exact tests were used to compare rates.
RESULTS: Infiltrating ductal carcinoma was the most common type of malignancy in the U.S. and China. The mean number of positive lymph nodes was higher in China (2.59 vs. 1.31, p < .001). Stage at diagnosis was higher in China (stage IIA vs. I, p < .001). Mean size of tumor at diagnosis was higher in China (32.63 vs. 21.57 mm). Mean age at diagnosis was lower in China (48.28 vs. 61.29 years, p < .001). Moreover, 2.0% of U.S. women underwent radical mastectomy compared with 12.5% in China, and 0.02% in China underwent reconstructive surgery.
CONCLUSION: Chinese women were diagnosed at younger ages with higher stage and larger tumors and underwent more aggressive surgical treatment. Prospective trials should be conducted to address screening, surgical, and tumor discrepancies between China and the U.S. IMPLICATIONS FOR PRACTICE: Breast cancer patients in China are diagnosed at later stages than those in America, which might contribute to different clinical management and lower 5-year survival rate. This phenomenon suggests that an earlier detection and treatment program should be widely implemented in China. By comparing the characteristics of Chinese and Chinese-American patients, we found significant differences in tumor size, lymph nodes metastasis, and age at diagnosis. These consequences indicated that patients with similar genetic backgrounds may have different prognoses due to the influence of environment and social economic determinates. ©AlphaMed Press.

Entities:  

Keywords:  Breast cancer; China; Disparities

Mesh:

Year:  2015        PMID: 26240131      PMCID: PMC4571797          DOI: 10.1634/theoncologist.2014-0290

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  15 in total

1.  Knowledge, attitudes, and behaviour regarding breast cancer screening among women from different socio-economic regions in southwest China: a cross-sectional study.

Authors:  Yuan Huang; Ke Zhou; Hui Li; Anrong Wang; Jiayuan Li; Yi Pang; Qiong Wang; Rong Huang; Liang Fu; Min Kang; Ping Ning; Ping Yuan
Journal:  Asian Pac J Cancer Prev       Date:  2011

2.  [Effectiveness and health economic analysis of strategies on cervical cancer screening and early diagnosis and treatment].

Authors:  Fang-hui Zhao; Jun-feng Chen; Xiao-hong Gao; Li-min Gao; Qi-gui Liu; Zhi-hua Liu; He Xu; Jun-fei Ma; Li Ma; Xiao-ling Xu; Shang-ying Hu; Yan Ning; Ju-fang Shi; You-lin Qiao
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2012-08

3.  Laterality of breast cancer in the United States.

Authors:  H A Weiss; S S Devesa; L A Brinton
Journal:  Cancer Causes Control       Date:  1996-09       Impact factor: 2.506

4.  Recognising symptoms of breast cancer as a reason for delayed presentation in Asian women--the psycho-socio-cultural model for breast symptom appraisal: opportunities for intervention.

Authors:  Nur Aishah Taib; Cheng-Har Yip; Wah-Yun Low
Journal:  Asian Pac J Cancer Prev       Date:  2011

5.  Risk factors related to female breast cancer in regions of Northeast China: a 1:3 matched case-control population-based study.

Authors:  Zhi-gang Yu; Cun-xian Jia; Cui-zhi Geng; Jin-hai Tang; Jin Zhang; Li-yuan Liu
Journal:  Chin Med J (Engl)       Date:  2012-03       Impact factor: 2.628

6.  Cancer survival in Africa, Asia, and Central America: a population-based study.

Authors:  Rengaswamy Sankaranarayanan; Rajaraman Swaminathan; Hermann Brenner; Kexin Chen; Kee Seng Chia; Jian Guo Chen; Stephen C K Law; Yoon-Ok Ahn; Yong Bing Xiang; Balakrishna B Yeole; Hai Rim Shin; Viswanathan Shanta; Ze Hong Woo; Nimit Martin; Yupa Sumitsawan; Hutcha Sriplung; Adolfo Ortiz Barboza; Sultan Eser; Bhagwan M Nene; Krittika Suwanrungruang; Padmavathiamma Jayalekshmi; Rajesh Dikshit; Henry Wabinga; Divina B Esteban; Adriano Laudico; Yasmin Bhurgri; Ebrima Bah; Nasser Al-Hamdan
Journal:  Lancet Oncol       Date:  2009-12-10       Impact factor: 41.316

7.  Age interactions in breast cancer: an analysis of a 10-year multicentre study in China.

Authors:  H J Yang; X F Yu; X M He; J H Fan; J Li; F Xu; B N Zhang; Z H Tang; S Zheng; Y L Qiao
Journal:  J Int Med Res       Date:  2012       Impact factor: 1.671

Review 8.  Breast cancer research in Asia: adopt or adapt Western knowledge?

Authors:  Nirmala Bhoo-Pathy; Cheng-Har Yip; Mikael Hartman; Cuno S P M Uiterwaal; Beena C R Devi; Petra H M Peeters; Nur Aishah Taib; Carla H van Gils; Helena M Verkooijen
Journal:  Eur J Cancer       Date:  2012-10-02       Impact factor: 9.162

9.  Breast cancer stage at diagnosis and area-based socioeconomic status: a multicenter 10-year retrospective clinical epidemiological study in China.

Authors:  Qiong Wang; Jing Li; Shan Zheng; Jia-Yuan Li; Yi Pang; Rong Huang; Bao-Ning Zhang; Bin Zhang; Hong-Jian Yang; Xiao-Ming Xie; Zhong-Hua Tang; Hui Li; Jian-Jun He; Jin-Hu Fan; You-Lin Qiao
Journal:  BMC Cancer       Date:  2012-03-29       Impact factor: 4.430

10.  A nation-wide multicenter 10-year (1999-2008) retrospective clinical epidemiological study of female breast cancer in China.

Authors:  Jing Li; Bao-Ning Zhang; Jin-Hu Fan; Yi Pang; Pin Zhang; Shu-Lian Wang; Shan Zheng; Bin Zhang; Hong-Jian Yang; Xiao-Ming Xie; Zhong-Hua Tang; Hui Li; Jia-Yuan Li; Jian-Jun He; You-Lin Qiao
Journal:  BMC Cancer       Date:  2011-08-22       Impact factor: 4.430

View more
  12 in total

Review 1.  Protecting Effects of Gonadotropin-Releasing Hormone Agonist on Chemotherapy-Induced Ovarian Damage in Premenopausal Breast Cancer Patients: A Systematic Review and Meta-Analysis.

Authors:  Fang Bai; Yunshu Lu; Kejin Wu; Qing Chen; Longlong Ding; Meixin Ge; Ziyi Weng
Journal:  Breast Care (Basel)       Date:  2017-02-28       Impact factor: 2.860

2.  Comparing Clinicopathologic Features and Surgical Treatment of Premenopausal Breast Cancer across Italy and China: Report from a Medical Exchange Program.

Authors:  Alessandro Fancellu; Xue Yun Zhao; Pietrina Cottu; Valeria Sanna; Yuan Ping Li; Qin Zhu; Cinzia Tanda; Ying Yi Zhang; Yan Mei Lai; Giorgio Carlo Ginesu; Shu Qin Dai; Alberto Porcu
Journal:  Breast Care (Basel)       Date:  2020-01-21       Impact factor: 2.860

3.  Estimated cancer incidence and mortality in Hebei province, 2012.

Authors:  Yutong He; Di Liang; Daojuan Li; Jingbo Zhai; Junqing Zhu; Jing Jin; Denggui Wen; Baoen Shan
Journal:  Chin J Cancer Res       Date:  2016-06       Impact factor: 5.087

4.  Enhancing the Screening Efficiency of Breast Cancer by Combining Conventional Medical Imaging Examinations With Circulating Tumor Cells.

Authors:  Yang Gao; Wan-Hung Fan; Chaohui Duan; Wenhe Zhao; Jun Zhang; Xixiong Kang
Journal:  Front Oncol       Date:  2021-05-19       Impact factor: 6.244

5.  Current Status and Factors Influencing Surgical Options for Breast Cancer in China: A Nationwide Cross-Sectional Survey of 110 Hospitals.

Authors:  Benlong Yang; Guosheng Ren; Erwei Song; Da Pan; Jing Zhang; Yongsheng Wang; Ning Liao; Jinhai Tang; Xiang Wang; Shude Cui; Feng Jin; Cuizhi Geng; Qiang Sun; Hongyuan Li; Zhimin Fan; Xuchen Cao; Haibo Wang; Shu Wang; Zhimin Shao; Jiong Wu
Journal:  Oncologist       Date:  2020-05-13       Impact factor: 5.837

6.  Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer.

Authors:  Chang Gong; Weige Tan; Kai Chen; Na You; Shan Zhu; Gehao Liang; Xinhua Xie; Qian Li; Yunjie Zeng; Nengtai Ouyang; Zhihua Li; Musheng Zeng; ShiMei Zhuang; Wan-Yee Lau; Qiang Liu; Dong Yin; Xueqin Wang; Fengxi Su; Erwei Song
Journal:  EBioMedicine       Date:  2016-08-17       Impact factor: 8.143

7.  Bioinformatics-based identification of miR-542-5p as a predictive biomarker in breast cancer therapy.

Authors:  Qiong-Ni Zhu; Helen Renaud; Ying Guo
Journal:  Hereditas       Date:  2018-01-15       Impact factor: 3.271

8.  Vertebral fractures among breast cancer survivors in China: a cross-sectional study of prevalence and health services gaps.

Authors:  Evelyn Hsieh; Qin Wang; Renzhi Zhang; Xin Niu; Weibo Xia; Liana Fraenkel; Karl L Insogna; Jing Li; Jennifer S Smith; Chunwu Zhou; You-Lin Qiao; Pin Zhang
Journal:  BMC Cancer       Date:  2018-01-30       Impact factor: 4.430

9.  LncRNA H19 is a major mediator of doxorubicin chemoresistance in breast cancer cells through a cullin4A-MDR1 pathway.

Authors:  Qiong-Ni Zhu; Guo Wang; Ying Guo; Yan Peng; Rui Zhang; Jun-Li Deng; Zhi-Xing Li; Yuan-Shan Zhu
Journal:  Oncotarget       Date:  2017-09-21

10.  Overall Survival and Local Recurrence Among Breast Cancer Patients in Hospital Sultanah Nora Ismail Batu Pahat, 2007-2013

Authors:  Sathesh Balasundram; Khairuzi Salekan; Fadya Nabiha Ahmad Shariffuddin; Nur Aishah Taib; Tassha Hilda Adnan
Journal:  Asian Pac J Cancer Prev       Date:  2018-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.